Gain Therapeutics, Inc.
GANX
$1.91
-$0.125-6.16%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | -100.00% | -100.00% | -58.37% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -100.00% | -100.00% | -100.00% | -58.37% |
| Cost of Revenue | -7.38% | 155.11% | 93.21% | 44.92% | 69.48% |
| Gross Profit | 7.01% | -157.75% | -94.72% | -47.27% | -71.57% |
| SG&A Expenses | -11.28% | -14.81% | -10.88% | -1.90% | 12.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -8.76% | -4.64% | -2.17% | 7.67% | 24.49% |
| Operating Income | 8.53% | 4.41% | 1.92% | -8.49% | -25.11% |
| Income Before Tax | 10.43% | 3.42% | 1.78% | -8.86% | -26.81% |
| Income Tax Expenses | 576.92% | -67.39% | -54.47% | -23.54% | -14.64% |
| Earnings from Continuing Operations | 8.34% | 3.83% | 2.08% | -8.68% | -26.59% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.34% | 3.83% | 2.08% | -8.68% | -26.59% |
| EBIT | 8.53% | 4.41% | 1.92% | -8.49% | -25.11% |
| EBITDA | 8.54% | 4.44% | 1.95% | -8.44% | -25.08% |
| EPS Basic | 45.18% | 37.73% | 27.07% | 6.45% | -17.34% |
| Normalized Basic EPS | 46.14% | 37.46% | 26.86% | 6.27% | -17.56% |
| EPS Diluted | 45.18% | 37.73% | 27.07% | 6.45% | -17.34% |
| Normalized Diluted EPS | 46.14% | 37.46% | 26.86% | 6.27% | -17.56% |
| Average Basic Shares Outstanding | 75.68% | 61.01% | 34.99% | 22.07% | 9.49% |
| Average Diluted Shares Outstanding | 75.68% | 61.01% | 34.99% | 22.07% | 9.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |